History of preoperative therapy for pancreatic cancer and the MD Anderson experience

Cameron E. Gaskill; Jessica Maxwell; Naruhiko Ikoma; Michael P. Kim; Ching Wei Tzeng; Jeffrey E. Lee; Matthew H.G. Katz

doi:10.1002/jso.26394

History of preoperative therapy for pancreatic cancer and the MD Anderson experience

Cameron E. Gaskill, Jessica Maxwell, Naruhiko Ikoma, Michael P. Kim, Ching Wei Tzeng, Jeffrey E. Lee, Matthew H.G. Katz

Surgical Oncology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy—a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.

Original language	English (US)
Pages (from-to)	1414-1422
Number of pages	9
Journal	Journal of surgical oncology
Volume	123
Issue number	6
DOIs	https://doi.org/10.1002/jso.26394
State	Published - May 1 2021

Keywords

chemoradiation
chemotherapy
neoadjuvant
pancreatic adenocarcinoma

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.26394

Cite this

@article{ec89938d9d9f41cca3661f31f2aecd54,

title = "History of preoperative therapy for pancreatic cancer and the MD Anderson experience",

abstract = "Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy—a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.",

keywords = "chemoradiation, chemotherapy, neoadjuvant, pancreatic adenocarcinoma",

author = "Gaskill, {Cameron E.} and Jessica Maxwell and Naruhiko Ikoma and Kim, {Michael P.} and Tzeng, {Ching Wei} and Lee, {Jeffrey E.} and Katz, {Matthew H.G.}",

note = "Funding Information: The manuscript was edited by Sarah Bronson, ELS, of the Research Medical Library at The University of Texas MD Anderson Cancer Center. We thank all of the members of our multidisciplinary treatment team. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = may,

day = "1",

doi = "10.1002/jso.26394",

language = "English (US)",

volume = "123",

pages = "1414--1422",

journal = "Journal of surgical oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - History of preoperative therapy for pancreatic cancer and the MD Anderson experience

AU - Gaskill, Cameron E.

AU - Maxwell, Jessica

AU - Ikoma, Naruhiko

AU - Kim, Michael P.

AU - Tzeng, Ching Wei

AU - Lee, Jeffrey E.

AU - Katz, Matthew H.G.

N1 - Funding Information: The manuscript was edited by Sarah Bronson, ELS, of the Research Medical Library at The University of Texas MD Anderson Cancer Center. We thank all of the members of our multidisciplinary treatment team. Publisher Copyright: © 2021 Wiley Periodicals LLC

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy—a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.

AB - Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy—a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.

KW - chemoradiation

KW - chemotherapy

KW - neoadjuvant

KW - pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85104013276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104013276&partnerID=8YFLogxK

U2 - 10.1002/jso.26394

DO - 10.1002/jso.26394

M3 - Review article

C2 - 33831256

AN - SCOPUS:85104013276

SN - 0022-4790

VL - 123

SP - 1414

EP - 1422

JO - Journal of surgical oncology

JF - Journal of surgical oncology

IS - 6

ER -

History of preoperative therapy for pancreatic cancer and the MD Anderson experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this